Consequently, OAS imposes a ‘primary addiction’ that modulates the target epitope specificity of the secondary antibody response and has wide-reaching consequences for vaccines that require seasonal updating, including influenza and SARS-CoV-2. The gene discussed is SMOC1; the disease is influenza.